Tuesday, November 24, 2009, 3:36am EST - Canadian Markets open in 5 hours and 54 minutes.
To create a watchlist or portfolio of shares, Sign-in or Register

Marshall Edwards Inc. (MSHL)

 On Nov 23: 0.7097 USD   0.00 (0.00%)  
MORE ON MSHL
Quotes
HereSummary
Charts
News & Info
Company
Analyst Coverage
Ownership
Financials
Marshall Edwards, Inc. (NGM:MSHL) Delayed quote dataEdit
Last Trade: 0.7097 USD
Trade Time: Nov 23
Change: 0.00 (0.00%)
Prev Close: 0.7097
Open: N/A
Bid: N/A
Ask: N/A
1y Target Est: N/A
Day's Range: N/A - N/A
52wk Range: 0.25 - 1.74
Volume: 0
Avg Vol (3m): 143,720
Market Cap: 52.14M
P/E (ttm): N/A
EPS (ttm): -0.145
Div & Yield: N/A (N/A%)
Marshall Edwards Inc. (MSHL)
1d  5d  3m  6m  1y  2y  5y  max 
 Add MSHL to Portfolio   Download Data

HEADLINES
• MARSHALL EDWARDS INC Financials
EDGAR Online Financials (Tue, Nov 17)
• MARSHALL EDWARDS INC Files SEC form 10-Q, Quarterly Report
EDGAR Online (Thu, Nov 12)
• Marshall Edwards, Inc.'s NV-128, a Novel mTOR Inhibitor, Demonstrates Good Safety Profile and High Anti-Cancer Activity In Vivo
Marketwire (Tue, Sep 29)
• MARSHALL EDWARDS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standa
EDGAR Online (Tue, Sep 22)
• Marshall Edwards, Inc. Receives Nasdaq Notice of Minimum Bid Price Non-Compliance
Marketwire (Tue, Sep 22)
• MARSHALL EDWARDS INC Files SEC form 10-K, Annual Report
EDGAR Online (Tue, Sep 1)
• MARSHALL EDWARDS INC Files SEC form 8-K, Entry into a Material Definitive Agreement
EDGAR Online (Fri, Aug 7)
• Marshall Edwards Licenses the Investigational Anti-Cancer Compound NV-128 From Novogen Limited
Marketwire (Wed, Aug 5)
• Researchers Discover That Phenoxodiol Kills Rapidly Proliferating T-Cells
Marketwire (Tue, Jul 7)
• Independent Data Monitoring Committee Reviews Marshall Edwards, Inc.'s Arrangements for Data Analysis of the Ovature Trial
Marketwire (Wed, Jun 17)
More Headlines for MSHL...
ANALYST
EPS Est (next year) (Jun-08) : N/A
EPS Est (in 2 years) (Jun-09) : N/A
Avg Rec (current)*: 1.0
PEG Ratio: N/A
* (Strong Buy) 1.0 - 5.0 (Strong Sell)
Analyst Opinion - Estimates

BUSINESS SUMMARY
Marshall Edwards, Inc., a developmental stage pharmaceutical company, engages in the development and commercialization of drugs for the treatment of cancer.

Full Company Profile

Add to My Portfolio Add to Portfolio    Email to a Friend Email to a Friend
Get Summary for Another Symbol:
Symbol Lookup
• Latest News • Canadian Indices